Sorrento Therapeutics, Inc.
4955 Directors Pl.
About Sorrento Therapeutics, Inc.
383 articles about Sorrento Therapeutics, Inc.
Sorrento Announces IND Filing for COVI-DROPS, an Intranasal Formulation of a High Potency Neutralizing Antibody Against SARS-CoV-2
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it is filing an investigational new drug application (IND) for intranasal (IN) COVI-DROPS (STI-2099) to study the safety and pharmacokinetics in both healthy volunteers and patients with mild COVID-19.
Sorrento Announces FDA IND Filing Today for COVI-AMG Neutralizing and High Potency Antibody Against SARS-CoV-2
IND filing today for STI-2020 (COVI-AMG™) for the treatment of COVID-19 in patients with mild symptoms and a separate safety and pharmacokinetic study in healthy volunteers. These initial trials are expected to be followed by pivotal trials with a goal of potentially receiving an EUA (Emergency Use Authorization). Animal model data (golden Syrian hamsters infected with SARS-CoV-2) demonstrated a highly effective neutralizing profile.
Sorrento Announces That Intranasal Administration of COVI-AMG™ Neutralizing Antibody Prevented COVID-19 Disease Progression in Infected Hamsters Following SARS-CoV-2 Infection
In an IND-enabling study, intranasal COVI-AMG nAb (STI-2099 or COVI-DROPSTM) very early on decreased COVID-19 disease severity and shortened the duration of the disease in infected hamsters
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Therapeutics’ Large Phase 2 Clinical Trial of Abivertinib in Mild, Moderate and Severe COVID-19 Patients
Phase 2 clinical trials of Abivertinib now cleared to proceed in both Brazil and the U.S. Studies are complementary and address both dose duration and disease stage Rapid enrollment expected for both geographies SAN DIEGO, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Phase 2 clinical trial of Abivertinib
Sorrento Adds Mesenchymal Stem Cell Program (MSC) That Has Been Cleared for a Phase 1 Trial by the FDA to the Pipeline of COVID-19 Focused Rescue Therapies
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has entered into an exclusive license agreement with Personalized Stem Cells, Inc. (PSC) to acquire global rights to its adipose derived mesenchymal stem cells (MSCs) for patients suffering from acute respiratory distress syndrome (ARDS) associated with COVID-19, which have been cleared for a Phase 1 clinical trial by the FDA. The study is a single arm, non-randomized P
Sorrento Therapeutics, Inc. released details about its upcoming COVID-19 Pipeline Update call and webcast on October 13th, 2020.
Sorrento Announces the Discovery of Salicyn-30 Small Molecule That Strongly Inhibits SARS-CoV-2 Infection in Preclinical Studies
In preclinical studies, Salicyn-30, a small molecule, demonstrated potent in-vitro viral load reduction of 3-4 log in SARS-CoV-2 infection model in normal healthy VERO E6 cells. Salicyn-30 displays a novel mechanism of inhibition of SARS-CoV-2, with potential additive benefits when used in a multi-modal therapy approach. Salicyn-30 can potentially be administered orally alone and will be tested in combination with Sorrento’s potent STI-1499 and affinity matured STI-2020 neutralizing antibo
Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to Complete Enrollment on its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program in 2020
SP-102 could potentially be the first FDA approved epidural steroid product for the treatment of sciatica with the potential to replace the current 10 to 11 million off-label epidural steroid injections administered each year in the U.S.
Sorrento Therapeutics, Inc. announced it will host a R&D Day conference call and simultaneous webcast on October 13th, 2020 focusing on its comprehensive multi-modal approach to COVID-19.
Sorrento Therapeutics and ViralClear Enter Into Agreement to Explore Combination Antibody Plus Antiviral Therapy Against COVID-19
ViralClear Pharmaceuticals, Inc. (Nasdaq BSGM) and Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced the companies are exploring the synergistic potential of small molecules and antibodies combination therapies against COVID-19.
Sorrento Releases Preclinical Data for STI-1499 (COVI-Guard™) and STI-2020 (COVI-AMG™), Potent Neutralizing Antibodies Against SARS-CoV-2
In preclinical studies, both STI-1499 and STI-2020 demonstrated potent neutralizing activity against SARS-CoV-2 virus isolates, including the emerging Spike D614G variant virus.
Sorrento Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) In Reduction of OsteoArthritis (OA) Knee Pain
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") released positive Phase 1b trial data (clinicaltrials.gov NCT03542838) of resiniferatoxin (RTX) with completed Day 84 effectiveness data (end-point analysis) for all patients and completed six-month follow-ups in all doses for all patients enrolled, with no negative safety signal as of September 2020.
Sorrento Therapeutics Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) Epidural in Cancer Patients with Reported Intractable Pain
Seventeen subjects with advanced cancer pain received epidural RTX (0.4 to 25 mcg). No dose limiting toxicities were reported. A majority of patients reported meaningful pain reduction of 30% or more from baseline. Sorrento expects to submit to the FDA a request to proceed with a Phase 3 clinical trial in this orphan indication imminently. SAN DIEGO, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced the public release of the results of it
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trial of STI-1499 (COVI-GUARD) Neutralizing Antibody in COVID-19 Positive Patients
Phase 1 clinical trial for STI-1499 (COVI-GUARD™) in hospitalized COVID-19 patients has received FDA notice that it may proceed with patient enrollment.
Sorrento Secures Exclusive License From Mayo Clinic for Antibody-Drug-Nanoparticle Albumin-Bound Immune Complex (ADNIC) Platform
Sorrento Therapeutics, Inc. announced it has entered into an exclusive license agreement with Mayo Clinic for a potential breakthrough technology platform that is capable of generating a great diversity of stable antibody-drug-nanoparticle albumin-bound immune complexes targeting many types of human diseases including various solid and liquid tumors.
Sorrento Announces the Closing of Its Acquisition of SmartPharm to Build Next Generation G-MAB-Encoded Plasmid DNA For Cost-Efficient and In Vivo Production of Antibody Therapeutics in Patients
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and SmartPharm Therapeutics, Inc. (“SmartPharm”) announced today that Sorrento has completed the acquisition of SmartPharm, a gene-encoded protein therapeutics company developing non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases with broad potential application in enhancing any antibody-centric therapeutics.
Sorrento Enters Into Merger Agreement to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies, Starting With Neutralizing Antibodies to Treat COVID-19 and Cancer Therapeutics
The combination of SmartPharm’s Gene Mab™ gene-encoded in vivo expression system and Sorrento’s SARS-CoV-2 neutralizing antibodies may potentially provide longer-acting, single injection protection against COVID-19. Beyond COVID-19, the synergies between Sorrento’s proprietary fully human G-MAB ™ Antibody Library and SmartPharm’s Gene-Encoded Therapeutics (GET) Platform are expected to provide a vast product pipeline of novel, long-acting therapeutic proteins for a broad range of diseases,
Sorrento Announces FDA IND Filing Today for COVI-GUARD Neutralizing and High Potency Antibody Against SARS-CoV-2
IND filing today for STI-1499 (COVI-GUARD™) for hospitalized COVID-19 patients. The initial trial is expected to be followed by pivotal trials with a goal of potentially receiving an EUA (Emergency Use Authorization) as early as the end of this year. Animal model data (Syrian Golden Hamsters infected with SARS-CoV-2) confirm the neutralizing profile and high potency of this antibody, expected effective dose in human to be at least 5 times lower than current known antibodies being assessed in
In its filing, Sorrento did not provide a reason for Shao’s termination.
Sorrento to Take Action Against Hindenburg Research for Statements Believed Intended to Manipulate Stock Price
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that it believes it has uncovered fraudulent attempts to manipulate the Company’s stock. On August 11, 2020, it was reported that an organization calling itself “Hindenburg Research” published claims regrading one of Sorrento’s COVID-19 diagnostic products. The report is believed to include false and/or misleading statements for the sole apparent purpose of negatively manipulat